person · Reporting owner

Cordani David

Disclosed activity across 3 companies

Tapewire entity: 47352
SEC CIK: 0001318751

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cigna GroupCI · Entity 550	Director · Chairman & CEO	May 12, 2026	May 14, 2026
GENERAL MILLS INCGIS · Entity 3236	Director	August 27, 2023	August 29, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cigna Group

Report date May 12, 2026 · Filed May 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	57,766	Ending reported balance After 2026-05-13 transaction · row 17 17 source rows · reconciled sequence Row 1 · 2026-05-12 · Exercise / conversion · Acquired 103,595 · Balance 150,696 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. Row 2 · 2026-05-12 · Exercise / conversion · Acquired 85,519 · Balance 236,215 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. Row 3 · 2026-05-12 · Sale · Disposed 3,903 · Balance 232,312 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F2: Represents the weighted average price of the shares sold. The prices actually received ranged from $286.43 to $287.425 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-05-12 · Sale · Disposed 14,292 · Balance 218,020 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F3: Represents the weighted average price of the shares sold. The prices actually received ranged from $287.43 to $288.42 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-05-12 · Sale · Disposed 13,839 · Balance 204,181 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F4: Represents the weighted average price of the shares sold. The prices actually received ranged from $288.435 to $289.41 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-05-12 · Sale · Disposed 41,099 · Balance 163,082 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F5: Represents the weighted average price of the shares sold. The prices actually received ranged from $289.435 to $290.43 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-05-12 · Sale · Disposed 13,732 · Balance 149,350 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F6: Represents the weighted average price of the shares sold. The prices actually received ranged from $290.44 to $291.438 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-05-12 · Sale · Disposed 12,315 · Balance 137,035 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F7: Represents the weighted average price of the shares sold. The prices actually received ranged from $291.44 to $292.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-05-12 · Sale · Disposed 7,861 · Balance 129,174 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F8: Represents the weighted average price of the shares sold. The prices actually received ranged from $292.44 to $293.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-05-12 · Sale · Disposed 2,142 · Balance 127,032 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F9: Represents the weighted average price of the shares sold. The prices actually received ranged from $293.46 to $294.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-05-12 · Sale · Disposed 38,487 · Balance 88,545 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F10: Represents the weighted average price of the shares sold. The prices actually received ranged from $294.46 to $295.453 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 12 · 2026-05-12 · Sale · Disposed 34,641 · Balance 53,904 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F11: Represents the weighted average price of the shares sold. The prices actually received ranged from $295.46 to $296.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 13 · 2026-05-12 · Sale · Disposed 2,017 · Balance 51,887 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F12: Represents the weighted average price of the shares sold. The prices actually received ranged from $296.46 to $297.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 14 · 2026-05-12 · Sale · Disposed 15,319 · Balance 36,568 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F13: Represents the weighted average price of the shares sold. The prices actually received ranged from $297.492 to $298.49 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 15 · 2026-05-12 · Sale · Disposed 2,231 · Balance 34,337 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F14: Represents the weighted average price of the shares sold. The prices actually received ranged from $298.495 to $298.675 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Row 16 · 2026-05-13 · Exercise / conversion · Acquired 15,458 · Balance 49,795 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. Row 17 · 2026-05-13 · Exercise / conversion · Acquired 7,971 · Balance 57,766 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28	Direct	15,458	Reported balance After 2026-05-12 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2026-05-12 · Exercise / conversion · Disposed 103,595 · Balance 15,458 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F16: This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28	Direct	0	Reported balance After 2026-05-13 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2026-05-13 · Exercise / conversion · Disposed 15,458 · Balance 0 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F16: This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28	Direct	7,971	Reported balance After 2026-05-12 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2026-05-12 · Exercise / conversion · Disposed 85,519 · Balance 7,971 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F17: This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28	Direct	0	Reported balance After 2026-05-13 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2026-05-13 · Exercise / conversion · Disposed 7,971 · Balance 0 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F17: This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019.
Common Stock, $.01 Par ValueSEC Table I · non-derivative	IndirectBy GRAT	440,798	Reported balance Holding disclosure · report date 2026-05-12 · row 18 Holding and transaction disclosures are not merged. 1 source row Row 18 · Balance 440,798
Common Stock, $.01 Par ValueSEC Table I · non-derivative	IndirectBy Trust	157,935	Reported balance Holding disclosure · report date 2026-05-12 · row 19 Holding and transaction disclosures are not merged. 1 source row Row 19 · Balance 157,935
Common Stock, $.01 Par ValueSEC Table I · non-derivative	IndirectBy 401(k)	1,803.1422	Reported balance Holding disclosure · report date 2026-05-12 · row 20 Holding and transaction disclosures are not merged. 1 source row Row 20 · Balance 1,803.1422 F15: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

Filing footnotes · ownership attribution and instrument terms

F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

F2: Represents the weighted average price of the shares sold. The prices actually received ranged from $286.43 to $287.425 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F3: Represents the weighted average price of the shares sold. The prices actually received ranged from $287.43 to $288.42 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F4: Represents the weighted average price of the shares sold. The prices actually received ranged from $288.435 to $289.41 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F5: Represents the weighted average price of the shares sold. The prices actually received ranged from $289.435 to $290.43 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F6: Represents the weighted average price of the shares sold. The prices actually received ranged from $290.44 to $291.438 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F7: Represents the weighted average price of the shares sold. The prices actually received ranged from $291.44 to $292.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F8: Represents the weighted average price of the shares sold. The prices actually received ranged from $292.44 to $293.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F9: Represents the weighted average price of the shares sold. The prices actually received ranged from $293.46 to $294.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F10: Represents the weighted average price of the shares sold. The prices actually received ranged from $294.46 to $295.453 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F11: Represents the weighted average price of the shares sold. The prices actually received ranged from $295.46 to $296.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F12: Represents the weighted average price of the shares sold. The prices actually received ranged from $296.46 to $297.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F13: Represents the weighted average price of the shares sold. The prices actually received ranged from $297.492 to $298.49 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F14: Represents the weighted average price of the shares sold. The prices actually received ranged from $298.495 to $298.675 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.

F15: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

F16: This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018.

F17: This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019.

GENERAL MILLS INC

Report date August 27, 2023 · Filed August 29, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,512	Reported balance After 2023-08-27 transaction · row 1 1 source row Row 1 · 2023-08-27 · Grant · Acquired 348 · Balance 8,512 F1: Common stock issued to Non-Employee Director in lieu of retainer under the 2022 Stock Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Common stock issued to Non-Employee Director in lieu of retainer under the 2022 Stock Compensation Plan.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cigna Holding Co

Report date December 20, 2018 · Filed December 26, 2018

Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $.25 Par ValueSEC Table I · non-derivative	Direct	Reported balance After 2018-12-20 transaction · row 1 1 source row Row 1 · 2018-12-20 · Disposition to issuer · Disposed 305,006 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
Common Stock, $.25 Par ValueSEC Table I · non-derivative	IndirectBy 401(k)	Reported balance After 2018-12-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-12-20 · Disposition to issuer · Disposed 1,640.1881 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.19 · Expires 2021-03-01	Direct	Reported balance After 2018-12-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-12-20 · Disposition to issuer · Disposed 189,610 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.43 · Expires 2022-02-28	Direct	Reported balance After 2018-12-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-20 · Disposition to issuer · Disposed 200,229 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.73 · Expires 2023-03-05	Direct	Reported balance After 2018-12-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-20 · Disposition to issuer · Disposed 206,843 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.04 · Expires 2024-02-26	Direct	Reported balance After 2018-12-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-12-20 · Disposition to issuer · Disposed 229,443 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25	Direct	Reported balance After 2018-12-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-12-20 · Disposition to issuer · Disposed 159,388 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01	Direct	Reported balance After 2018-12-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-12-20 · Disposition to issuer · Disposed 142,801 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28	Direct	Reported balance After 2018-12-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-12-20 · Disposition to issuer · Disposed 119,053 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28	Direct	Reported balance After 2018-12-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-12-20 · Disposition to issuer · Disposed 93,490 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F8: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.
Phantom Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-12-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-12-20 · Disposition to issuer · Disposed 3,120.6486 · Balance 0 F9: The phantom stock units described in Table II are credited under the Cigna Executive Deferred Compensation Plan. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash. F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.

F4: This option was fully vested and exercisable at the time of the Merger.

F5: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.

F6: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.

F7: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.

F8: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

F9: The phantom stock units described in Table II are credited under the Cigna Executive Deferred Compensation Plan. Each phantom stock unit of Cigna is the economic equivalent of one share of Cigna Common Stock that would have been settled in cash. Under the Merger Agreement, each phantom stock unit of Cigna was exchanged for one phantom stock unit of New Cigna, which is the economic equivalent of one share of New Cigna Common Stock and will be settled in cash.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 13, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	7,971	$0.00 Strike: $197.35	$0.00	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · derivative · entry 24 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 7,971 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F17 · shares: This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019. Read SEC document
May 13, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	15,458	$0.00 Strike: $149.14	$0.00	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · derivative · entry 22 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 15,458 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F16 · shares: This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018. Read SEC document
May 13, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	7,971	$197.35	$1,573,076.85	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 17 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. Read SEC document
May 13, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	15,458	$149.14	$2,305,328.83	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 16 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	85,519	$0.00 Strike: $197.35	$0.00	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · derivative · entry 23 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,971 Underlying: Common Stock, $.01 Par Value · 85,519 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F17 · shares: This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	103,595	$0.00 Strike: $149.14	$0.00	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · derivative · entry 21 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,458 Underlying: Common Stock, $.01 Par Value · 103,595 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F16 · shares: This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	2,231	$298.53	$666,026.68	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 15 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,337 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F14 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $298.495 to $298.675 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	15,319	$298.24	$4,568,735.50	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 14 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,568 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F13 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $297.492 to $298.49 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	2,017	$296.84	$598,717.61	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 13 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,887 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F12 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $296.46 to $297.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	34,641	$295.98	$10,253,195.60	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 12 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,904 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F11 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $295.46 to $296.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	38,487	$294.98	$11,352,887.56	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 11 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,545 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F10 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $294.46 to $295.453 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	2,142	$293.92	$629,574.50	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 10 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,032 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F9 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $293.46 to $294.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	7,861	$292.88	$2,302,310.81	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 9 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,174 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F8 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $292.44 to $293.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	12,315	$291.95	$3,595,313.76	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 8 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,035 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F7 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $291.44 to $292.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	13,732	$291.01	$3,996,088.90	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 7 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,350 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F6 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $290.44 to $291.438 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	41,099	$290.00	$11,918,783.98	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 6 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,082 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F5 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $289.435 to $290.43 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	13,839	$288.85	$3,997,456.04	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 5 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,181 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F4 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $288.435 to $289.41 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	14,292	$287.96	$4,115,590.06	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 4 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,020 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $287.43 to $288.42 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	3,903	$286.83	$1,119,505.30	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 3 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,312 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $286.43 to $287.425 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	85,519	$197.35	$16,877,174.65	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 2 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. Read SEC document
May 12, 2026 Filed May 14, 2026 20:47 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	103,595	$149.14	$15,449,640.33	Disclosure SEC source: 0001739940-26-000044 · wk-form4_1778791641.xml · nonDerivative · entry 1 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:16 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	37,516	$0.00 Strike: $287.55	$0.00	Disclosure SEC source: 0001739940-26-000009 · wk-form4_1772583366.xml · derivative · entry 8 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,516 Underlying: Common Stock, $.01 Par Value · 37,516 shares Expires 2036-02-27 F6 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2027. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:16 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	4,408	$287.55	$1,267,520.40	Disclosure SEC source: 0001739940-26-000009 · wk-form4_1772583366.xml · nonDerivative · entry 4 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,101 F4 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:16 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	11,024	$287.55	$3,169,951.20	Disclosure SEC source: 0001739940-26-000009 · wk-form4_1772583366.xml · nonDerivative · entry 3 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,509 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:16 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	17,389	$0.00	$0.00	Disclosure SEC source: 0001739940-26-000009 · wk-form4_1772583366.xml · nonDerivative · entry 2 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,533 F2 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2027. Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:16 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	23,788	$0.00	$0.00	Disclosure SEC source: 0001739940-26-000009 · wk-form4_1772583366.xml · nonDerivative · entry 1 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,144 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
November 03, 2025 Filed Nov 3, 2025 19:47 UTC	Cigna Group CI · Entity 550	PurchaseCommon Stock, $.01 Par Value	4,134	$241.88	$999,916.21	Disclosure SEC source: 0001318751-25-000004 · wk-form4_1762199272.xml · nonDerivative · entry 1 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 157,935 F1 · price: Represents the weighted average price of the shares purchased. The prices actually paid ranged from $241.876 to $241.97 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document
March 03, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	26,527	$308.12	$8,173,499.24	Disclosure SEC source: 0001225208-25-002922 · doc4.xml · nonDerivative · entry 5 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,767 F6 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	39,476	$0.00 Strike: $305.86	$0.00	Disclosure SEC source: 0001225208-25-002922 · doc4.xml · derivative · entry 9 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,476 Underlying: Common Stock, $.01 Par Value · 39,476 shares Expires 2035-02-28 F8 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2026. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	22,910	$305.86	$7,007,252.60	Disclosure SEC source: 0001225208-25-002922 · doc4.xml · nonDerivative · entry 4 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,294 F5 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	4,696	$305.86	$1,436,318.56	Disclosure SEC source: 0001225208-25-002922 · doc4.xml · nonDerivative · entry 3 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,204 F4 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	11,117	$0.00	$0.00	Disclosure SEC source: 0001225208-25-002922 · doc4.xml · nonDerivative · entry 2 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,900 F3 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2026. Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:52 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	49,437	$0.00	$0.00	Disclosure SEC source: 0001225208-25-002922 · doc4.xml · nonDerivative · entry 1 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,783 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2022-2024 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. F2 · balance_after: Reflects the transfer by the Reporting Person of 334,387 shares of common stock on May 8, 2024 to the Reporting Person's grantor retained annuity trust. In addition, it reflects the transfer by the Reporting Person's grantor retained annuity trust of 99,918 shares of common stock on January 27, 2025 in respect of a payment of an annual annuity to the Reporting Person pursuant to the terms of the grantor retained annuity trust. Read SEC document
March 26, 2024 Filed Mar 28, 2024 21:14 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	7,761	$0.00 Strike: $139.22	$0.00	Disclosure SEC source: 0001225208-24-004608 · doc4.xml · derivative · entry 5 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 7,761 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F3 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
March 26, 2024 Filed Mar 28, 2024 21:14 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	7,761	$139.22	$1,080,486.42	Disclosure SEC source: 0001225208-24-004608 · doc4.xml · nonDerivative · entry 1 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 355,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document
March 25, 2024 Filed Mar 25, 2024 22:19 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	31,209	$0.00 Strike: $139.22	$0.00	Disclosure SEC source: 0001225208-24-004481 · doc4.xml · derivative · entry 12 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,761 Underlying: Common Stock, $.01 Par Value · 31,209 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F6 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
March 25, 2024 Filed Mar 25, 2024 22:19 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	31,209	$355.17	$11,084,356.97	Disclosure SEC source: 0001225208-24-004481 · doc4.xml · nonDerivative · entry 6 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 348,054 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F4 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $355.00 to $355.70 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
March 25, 2024 Filed Mar 25, 2024 22:19 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	31,209	$139.22	$4,344,916.98	Disclosure SEC source: 0001225208-24-004481 · doc4.xml · nonDerivative · entry 5 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 379,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document
March 22, 2024 Filed Mar 25, 2024 22:19 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	6,338	$0.00 Strike: $139.22	$0.00	Disclosure SEC source: 0001225208-24-004481 · doc4.xml · derivative · entry 11 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,970 Underlying: Common Stock, $.01 Par Value · 6,338 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F6 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
March 22, 2024 Filed Mar 25, 2024 22:19 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	6,338	$355.11	$2,250,682.11	Disclosure SEC source: 0001225208-24-004481 · doc4.xml · nonDerivative · entry 4 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 348,054 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $355.00 to $355.46 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
March 22, 2024 Filed Mar 25, 2024 22:19 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	6,338	$139.22	$882,376.36	Disclosure SEC source: 0001225208-24-004481 · doc4.xml · nonDerivative · entry 3 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 354,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document
March 21, 2024 Filed Mar 25, 2024 22:19 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,293	$0.00 Strike: $139.22	$0.00	Disclosure SEC source: 0001225208-24-004481 · doc4.xml · derivative · entry 10 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,308 Underlying: Common Stock, $.01 Par Value · 2,293 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F6 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
March 21, 2024 Filed Mar 25, 2024 22:19 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	2,293	$355.02	$814,051.69	Disclosure SEC source: 0001225208-24-004481 · doc4.xml · nonDerivative · entry 2 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 348,054 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $355.00 to $355.13 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
March 21, 2024 Filed Mar 25, 2024 22:19 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	2,293	$139.22	$319,231.46	Disclosure SEC source: 0001225208-24-004481 · doc4.xml · nonDerivative · entry 1 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document
March 14, 2024 Filed Mar 14, 2024 22:09 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	7,616	$0.00 Strike: $139.22	$0.00	Disclosure SEC source: 0001225208-24-004255 · doc4.xml · derivative · entry 14 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,601 Underlying: Common Stock, $.01 Par Value · 7,616 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F8 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
March 14, 2024 Filed Mar 14, 2024 22:09 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	7,616	$139.22	$1,060,299.52	Disclosure SEC source: 0001225208-24-004255 · doc4.xml · nonDerivative · entry 8 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 348,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document
March 13, 2024 Filed Mar 14, 2024 22:09 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	13,761	$0.00 Strike: $139.22	$0.00	Disclosure SEC source: 0001225208-24-004255 · doc4.xml · derivative · entry 13 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,217 Underlying: Common Stock, $.01 Par Value · 13,761 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F8 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
March 13, 2024 Filed Mar 14, 2024 22:09 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	7,108	$347.65	$2,471,125.34	Disclosure SEC source: 0001225208-24-004255 · doc4.xml · nonDerivative · entry 7 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 340,438 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F6 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $347.305 to $348.25 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
March 13, 2024 Filed Mar 14, 2024 22:09 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	4,972	$346.88	$1,724,682.89	Disclosure SEC source: 0001225208-24-004255 · doc4.xml · nonDerivative · entry 6 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 347,546 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F5 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $346.29 to $347.25 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
March 13, 2024 Filed Mar 14, 2024 22:09 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	892	$348.66	$311,003.38	Disclosure SEC source: 0001225208-24-004255 · doc4.xml · nonDerivative · entry 5 Cordani David · CIK 0001318751 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,518 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F4 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $348.345 to $348.85 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.